Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.06 CHF | +1.04% | +0.12% | +18.48% |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
May. 22 | Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars | MT |
Sales 2024 * | 10.29B 9.28B | Sales 2025 * | 10.96B 9.88B | Capitalization | 15.25B 13.75B |
---|---|---|---|---|---|
Net income 2024 * | 710M 640M | Net income 2025 * | 974M 878M | EV / Sales 2024 * | 1.78 x |
Net Debt 2024 * | 3.12B 2.81B | Net Debt 2025 * | 2.73B 2.46B | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
15.6
x | Employees | 22,633 |
Yield 2024 * |
1.79% | Yield 2025 * |
2.31% | Free-Float | 91.29% |
Latest transcript on Sandoz Group AG
1 day | +1.04% | ||
1 week | +0.12% | ||
1 month | +2.92% | ||
3 months | +16.75% | ||
6 months | +28.19% | ||
Current year | +18.48% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 32.06 | +1.04% | 1,999,753 |
24-05-30 | 31.73 | +0.51% | 583,968 |
24-05-29 | 31.57 | -2.23% | 930,222 |
24-05-28 | 32.29 | -0.68% | 595,126 |
24-05-27 | 32.51 | +1.53% | 438,205 |
Delayed Quote Swiss Exchange, May 31, 2024 at 11:30 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.48% | 15.25B | |
+15.91% | 41.97B | |
+22.40% | 22.34B | |
+16.12% | 14B | |
+45.12% | 12.06B | |
-9.58% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B | |
+4.00% | 4.62B |
- Stock Market
- Equities
- SDZ Stock